NCT06569251View on ClinicalTrials.gov

Adverse Neonatal Outcomes with a Shortened Clinical Regimen of Dexamethasone.

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

November 24, 2024

Study Completion Date

November 24, 2024

Conditions
Preterm BirthDistress Respiratory Syndrome
Interventions
DRUG

Dexamethasone 12 mg QD

Administration of dexamethasone to the mother as an inducer of fetal lung maturity. shortened scheme

DRUG

Dexamethasone 6 mg BID

Administration of dexamethasone to the mother as an inducer of fetal lung maturity. standard Scheme

Trial Locations (1)

11101

Hospital Escuela, Tegucigalpa

All Listed Sponsors
lead

Ricardo A Gutierrez Ramirez, MD, MSc, FACOG

OTHER

NCT06569251 - Adverse Neonatal Outcomes with a Shortened Clinical Regimen of Dexamethasone. | Biotech Hunter | Biotech Hunter